# US 2014/0271595 A1 · Use of a combination of d-aspartic and l-aspartic acids or salts thereof for the treatment of male infertility

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271595 A1
- Document ID: US20140271595A1
- Status: Published application
- Kind: A1
- Application number: 14/288,439
- Filed: 2014-05-28
- Published: 2014-09-18
- Earliest claimed: 2009-05-19
- Assignees: Merck Serono SA
- Applicants: MERCK SERONO S.p.A.
- Inventors: SALVATORE D'ANIELLO; ENRICO D'ANIELLO
- Web page: https://patentgrep.com/patent/US20140271595A1

## CPC

- A61K 33/30: Zinc; Compounds thereof
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/10: for impotence
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns the use of a combination consisting of D-aspartic and L-aspartic acids or L-aspartic acid used alone to stimulate the procreative activity in the man by increment of spermatozoon number and motility.

## Claims

### Claim 1

A method of treating male infertility comprising the administration of a composition to an infertile male, said composition comprising one or more pharmaceutically acceptable excipient and/or coadjuvant and:
a) a combination of D-aspartic acid or one or more alkaline or alkaline earth metal salts thereof and L-aspartic acid or one or more alkaline or alkaline earth metal salts thereof; or
b) comprising L-aspartic acid or one or more alkaline or alkaline earth metal salt thereof, alone.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said composition consists of one or more pharmaceutically acceptable excipient and/or coadjuvant and:
a) a combination of D-aspartic acid or one or more alkaline or alkaline earth metal salts thereof and L-aspartic acid or one or more alkaline or alkaline earth metal salts thereof; or
b) L-aspartic acid or one or more alkaline or alkaline earth metal salt thereof alone.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the concentration of D-aspartic acid or salts thereof is from 50% to 99.5% and the concentration of L-aspartic acid or salts thereof is from 0.05% to 50%, said percentages based on total weight of D-aspartic and L-aspartic acids or salts thereof in said composition.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the concentration of D-aspartic acid or salts thereof is from 50% to 80% and the concentration of L-aspartic acid or salts thereof is from 20% to 50%, said percentages based on total weight of D-aspartic and L-aspartic acids or salts thereof.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said coadjuvants are selected form the group consisting of amino acids, ketoacids, vitamins, minerals, reproductive function stimulating hormones, kallikrein, antibiotics, anti-inflammatory agents, antiandrogens, androgens, pentoxifilline, gonadotropine, gonadotropine releasing hormone (GnRH), adrenergic stimulators, dietetic supplements, anti-oxidants, and ketoacids.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said amino acids are selected from the group consisting of alanine, arginine, carnitine, cysteine, glutamine, glycine, leucine, lysine, isoleucine, methionine, ornithine, phenyl alanine, threonine, tryptophan, valine, and serine.

### Claim 7 (depends on 5)

The method according to claim 5, wherein said vitamins are selected from the group consisting of vitamin A, C, D3, E, K, B1, B2, B6, B12, PP, biotin (H), folic acid, lipoic acid and Q10 coenzyme.

### Claim 8 (depends on 5)

The method according to claim 5, wherein said minerals are selected from the group consisting of magnesium, potassium, zinc, manganese, molybdenum, chromium, selenium, calcium, iron, copper, iodine, phosphorus, and fluorine.

### Claim 9 (depends on 7)

The method according to claim 7, wherein the concentrations of vitamins are: vitamin A from 0.0048% to 0.024%, vitamin C from 0.36% to 3.6%, vitamin D3 from 0.00003% to 0.00015%, vitamin E from 0.06% to 0.6%, vitamin K from 0.00042% to 0.0021%, vitamin B1 from 0.0084 to 0.042%, vitamin B2 from 0.0096% to 0.048%, vitamin B6 from 0.012% to 0.06%, vitamin B12 from 6,10−6% to 3,10−5%, vitamin PP from 0.108% to 0.54%, biotin from 0.0009% to 4.4,10−5%, folic acid from 0.0012% to 0.006%, said percentages being % weight based on total composition weight.

### Claim 10 (depends on 8)

The method according to claim 8, wherein the concentrations of minerals are: magnesium from 3.2% to 9%, potassium from 0.4% to 4%, zinc from 0.09% to 0.45%, manganese from 0.02% to 0.07%, molybdenum, chromium or selenium from 0.0003% to 0.002%, calcium pantothenate from 0.04% to 0.15%, iron from 0.084% to 0.021%, copper from 0.02% to 0.1%, iodine from 0.0009% to 0.0045%, phosphorus from 2.5% to 20%, fluorine from 0.005% to 0.02%, calcium from 3.24% to 16.2%, said percentages being % weight based on total composition weight.

### Claim 11 (depends on 5)

The method according to claim 5, wherein the concentrations of amino acids in addition to D-aspartic and L-aspartic acids is from 0.6% weight to 10% weight based on total composition weight.

### Claim 12 (depends on 1)

The method according to claim 1, wherein said composition further comprises folic acid, vitamin B6, vitamin B12, potassium sorbate and sodium benzoate.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said folic acid concentration is from 0.002% to 0.006%, said Vitamin B6 concentration is from 0.02% to 0.06%, said Vitamin B12 concentration is from 1·10−5% to 3·10−5%, said potassium sorbate concentration is from 0.002 to 0.008%, and said sodium benzoate concentration is from 0.002 to 0.008%.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the infertility of said infertile male is not obstructive infertility as characterized by oligo and/or astenozoospermia with or without hypogonadotropic hypogonadism.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the daily dose of said composition is from 0.001 g/day to 10 g/day.
